<aside> 📘

TIF TOPICS IN FOCUS · 2025 · DEEP WIKI A revision dashboard and source-located clinical navigation note for TDT, NTDT and alpha-thalassaemia, built from the complete 45-page TIF booklet.

Source TIF 2025, 45 pp. · Zotero N4GX98NZ · PDF XLZFIVBS · Locators [1, p. x] = printed booklet pages · Created 2026-09-19

🖥️ Interactive version with live calculators: Thalassaemia Transfusion (TIF 2025)

</aside>

https://claude.ai/artifact/PF9n9qxwjyyKRAB5y19uLc

📑 Contents

PART A · Five-minute revision dashboard

<aside> 🩸

A red-cell unit is not the treatment. The treatment is a purposeful, longitudinal transfusion programme: define phenotype and objective, prescribe the regimen, select a safe component, then repeatedly test whether benefit still outweighs burden. [1, pp. 4–25, 30–34, 38–43]

</aside>

Your five-minute route

MIN	QUESTION	HIGH-YIELD ANSWER
1	Why transfuse now?	Start with steady-state phenotype, symptoms, growth, ineffective erythropoiesis and complications, not genotype or one Hb value alone.
2	Which lane?	TDT is usually sustained support; NTDT is commonly episodic or goal-directed; alpha-thalassaemia needs functional-haemoglobin-aware individualisation.
3	What is prescribed?	Write target, interval, dose or units, rate, monitoring and the clinical outcome expected. An interval copied forward is not a prescription.
4	What makes the unit safe?	Protect the complete antibody and reaction history; match deliberately; use component modification only for a documented indication.
5	What has changed?	Review benefit, pre-transfusion Hb trend, symptoms, reactions, alloimmunisation, iron, spleen, burden and whether the original indication remains valid.

<aside> 🩺

DECIDE BY PHENOTYPE For suspected TDT, a regular programme follows repeated evidence of disease burden. A transient infectious fall or one top-up transfusion must not silently become lifelong treatment. [1, pp. 5–6]

</aside>

<aside> 🎯

PRESCRIBE THE WHOLE REGIMEN For most TDT, the usual pre-transfusion target is 9.5–10.5 g/dL, generally every 2–5 weeks. A 10–11 g/dL target may be appropriate in selected settings. [1, pp. 7–10]

</aside>

<aside> 🧬

PREVENT AVOIDABLE HARM Before regular donor exposure, obtain extended red-cell phenotype or genotype where possible; preserve every historical alloantibody even if the current screen is negative. [1, pp. 6–7, 17–19]

</aside>

Compare the phenotype lanes

<aside> 🩸

TDT Regular, long-term support to sustain function and suppress ineffective erythropoiesis.

Trap: do not reduce initiation to genotype or one Hb result.

</aside>

<aside> ⏱️

NTDT Acute, episodic or time-limited support for a defined clinical aim; regular support only after individual appraisal.

Trap: do not let a goal-directed programme continue by inertia.

</aside>

<aside> 🧬

ALPHA-THALASSAEMIA / HbH On-demand or individualised regular support, guided by phenotype and effective Hb where relevant.

Trap: total Hb can overstate useful oxygen carriage.

</aside>

Pre-issue safety card

<aside> 🛡️

Before the unit leaves the blood bank

Know the red-cell profile: obtain extended phenotype or genotype before regular exposure where possible.
Match deliberately: ABO, Rh C/c/D/E/e and K compatibility are the TIF baseline for regular transfusion.
Never lose history: historical antibodies and clinically significant reactions matter even when today’s screen is negative.
Join the safety chain: leucoreduction, identification, bedside checks, reaction recognition and haemovigilance work together. [1, pp. 6–7, 12–19] </aside>

<aside> ⚠️

Four revision traps

A number is not an indication: separate baseline disease from reversible or intercurrent illness.
“Fresh” is not enough: appropriate antigen matching is preventive care.
Every unit has a cost: track iron, interval, cumulative use, chelation, organ assessment and practical burden.
Dependence can change: NTDT and alpha-thalassaemia programmes require reassessment, not inertia. [1, pp. 5–6, 17–18, 20–22, 31–34, 40–43] </aside>

Twenty-second flashcards

➕ What specific outcome does transfusion aim to change?
➕ What must a complete transfusion prescription include?
➕ What history must travel with the patient?
➕ What would make you continue, tailor, pause or stop the programme?

<aside> 🧭

Use safely This dashboard is a rapid revision and MDT-navigation aid, not an autonomous prescription. Local blood-bank policy, component availability, haemovigilance requirements and patient-specific specialist judgement remain controlling.

</aside>